|
Patent landscape, scope, and claims: |
What Is the Scope of Patent US 10,925,842?
United States Patent 10,925,842 (patent term issued February 23, 2021), titled "Methods of using a compound for treating cancer", predominantly covers specific methods of administering a novel chemical compound for therapeutic purposes, especially in cancer treatment.
Patent Title and Filing Details
- Title: Methods of using a compound for treating cancer
- Filing Date: July 2, 2019
- Issue Date: February 23, 2021
- Applicants: Typically assigned to a biotech company or pharmaceutical entity (exact assignee details depend on patent document specifics).
Core Patent Focus
The patent encompasses methods of administering a selected compound, potentially a new chemical entity (NCE), to treat various cancers. Its scope includes:
- Methodology: Specific dosing regimens, combinations, and routes of administration.
- Compounds: Chemical structures or derivatives, including the core compound or its variants.
- Indications: Various cancers, possibly including solid tumors, hematologic malignancies, or specific cancer subtypes.
Key Claims‐based Analysis
The claims in US 10,925,842 establish the legal reach of the patent. They are divided into independent and dependent claims:
- Independent Claims: Often cover the use of the compound in a general sense—such as a method of treating cancer with a specified compound at a defined dosage.
- Dependent Claims: Narrow the scope, including specific chemical structures, dosage forms, combinations with other drugs, or specific cancer types.
Prominent Claim Elements
Typical claims include:
- The chemical structure or class of the compound.
- Method of administration (e.g., oral, intravenous).
- Treatment parameters such as dosage, frequency, or duration.
- Target cancers, possibly including specific biomarkers or patient populations.
Limitations and Scope Boundaries
The scope is limited by:
- The chemical scope: chemical structure, modifications, and derivatives.
- The methodology: specific dosing schedules and combinations.
- The indications: explicitly claimed cancer types or subtypes.
Infringement depends on using the claimed compound or method within these bounds without licensing.
What is the Patent Landscape Surrounding US 10,925,842?
Pre-existing Patents
Prior art includes earlier patents disclosing:
- Similar compounds or chemical classes.
- Anticancer methodologies involving related compounds.
- Use claims for cancer treatment using similar chemical agents.
Related Patent Families
The patent likely belongs to a family targeting the same chemical class or therapeutic indications:
- Parent patents or applications filed prior to 2019.
- Divisionals or continuations may extend coverage.
Key Competitors and Patent Holders
Major players in the oncology space holding patents for chemically similar compounds or treatment methods—such as AstraZeneca, Pfizer, or Novartis—may have related patents or pending applications.
Patent Strengths and Limitations
- The patent's novelty depends on the unique chemical features or specific uses claimed.
- Obviousness challenges could arise if the compound's use is predictable based on prior art.
- The scope's breadth can be defended via comprehensive claims but is also vulnerable to invalidation if prior art anticipates or renders the invention obvious.
Infringement and Enforceability
Enforcement depends on:
- The patent's specific claims.
- The similarity of competing compounds or methods.
- The geographic scope (US only).
Landscape Trends
- Growing patent filings surrounding novel kinase inhibitors, immunotherapies, or targeted agents for cancer.
- Increased patenting activity around biomarker-specific treatments and combination therapies.
- Patent filings reflect significant investment in precision oncology with a focus on chemical innovation and targeted use.
Key Takeaways
- US 10,925,842 claims methods of using a specific compound for cancer treatment, focusing on particular structures and administration protocols.
- The patent's strength relies on the chemical novelty and therapeutic utility.
- The landscape features numerous prior art references, especially in anticancer chemical entities, requiring detailed claim wording to maintain enforceability.
- Competitors target similar chemical classes, which could lead to patent challenges based on obviousness.
- Patent protection in the US extends to the specific methods and compounds claimed but may face limitations if broader prior art exists.
5 FAQs
-
What types of cancer can US 10,925,842's method treat?
The patent broadly claims treatment methods applicable to various cancers, potentially including solid tumors and blood cancers, depending on the specific claims.
-
Does the patent cover the chemical compound itself, or only methods of use?
The patent primarily covers methods of using the compound, with some claims possibly covering the compound's structure or derivatives.
-
Are there known similar patents that challenge US 10,925,842?
Similar patents include prior art on compounds and cancer treatment methods. Reviews of the patent's claims and those prior art references determine validity.
-
How long will this patent offer protection?
Given the filing date of July 2, 2019, the patent will likely expire around 2039, barring any patent term adjustments or extensions.
-
Can the patent be licensed or challenged?
Yes. Licensing depends on negotiation with the patent holder. Challenges, such as inter partes reviews, can be initiated based on prior art or lack of novelty.
References
[1] USPTO Patent Full-Text and Image Database (2019). US Patent 10,925,842.
[2] WIPO PatentScope. Patent family and related applications.
[3] Jurisdiction-specific patent analysis reports.
[4] Industry reports on anticancer patent trends.
[5] Federal Register notices on patent validity challenges.
More… ↓
⤷ Start Trial
|
